Morgan Stanley

Analysts at BMO Capital, Evercore ISI, CICC, and Autonomous Research have all raised price targets in July 2026, with targets ranging from $240 to $270, implying meaningful upside from current levels. The consensus 'Outperform' rating from 25 analysts reflects confidence in Morgan Stanley's earnings trajectory and growth potential.

GF Value™ metrics indicate Morgan Stanley is significantly overvalued, with a fair value estimate of $151.11 versus a current trading price of $213.93 — a 41.6% premium. Despite the positive analyst ratings, the stock's current price exceeds even some of the more optimistic analyst target ranges, raising concerns about stretched valuation.

Morgan Stanley's broad exposure to capital markets means it stands to benefit from continued AI-driven investment banking activity and wealth management growth. Strong prior-quarter earnings beats and raised guidance reinforce optimism that AI-related deal flow and asset appreciation will sustain revenue momentum into the next year.

Morgan Stanley's own research flags AI spending as an 'ongoing market concern,' signaling potential headwinds from a cooling AI investment cycle. Analysts have also noted contradictions in forecasts around semiconductor profitability slowdowns, raising doubts about whether AI-driven revenue tailwinds for financial firms like Morgan Stanley are durable.

Technical analysis shows Morgan Stanley in a clear uptrend of higher highs and higher lows, with bullish signals from the GoNoGo composite indicator and the parabolic SAR. The stock's strong recovery near all-time highs after a brief dip reinforces positive price momentum heading into the next earnings cycle.

Despite the positive price chart, institutional money flow indicators are distinctly negative, with large capital not actively flowing into the stock. A bearish MACD crossover preceded the most recent dip, and slowing volume trends suggest waning conviction among institutional investors, potentially capping near-term upside.